The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group
Abstract
Purpose: To determine the accuracy of positron emission tomography with fluorine-18–labeled 2-fluoro-2-deoxy-d-glucose (FDG-PET) in detecting axillary nodal metastases in women with primary breast cancer. Patients and Methods: In this prospective multicenter study, 360 women with newly diagnosed invasive breast cancer underwent FDG-PET. Images were blindly interpreted by three experienced readers for abnormally increased axillary FDG uptake. Imaging results from 308 assessable axillae were compared with axillary node pathology. Results: For detecting axillary nodal metastasis, the mean estimated area under the receiver operator curve for the three readers was 0.74 (range, 0.70 to 0.76). If at least one probably or definitely abnormal axillary focus was considered positive, the mean (and range) sensitivity, specificity, and positive and negative predictive values for PET were 61% (54% to 67%), 80% (79% to 81%), 62% (60% to 64%), and 79% (76% to 81%), respectively. False-negative axillae on PET had significantly smaller and fewer tumor-positive lymph nodes (2.7) than true-positive axillae (5.1; P < .005). Semiquantitative analysis of axillary FDG uptake showed that a nodal standardized uptake value (lean body mass) more than 1.8 had a positive predictive value of 90%, but a sensitivity of only 32%. Finding two or more intense foci of tracer uptake in the axilla was highly predictive of axillary metastasis (78% to 83% positive predictive value), albeit insensitive (27%). Conclusion: FDG-PET has moderate accuracy for detecting axillary metastasis but often fails to detect axillae with small and few nodal metastases. Although highly predictive for nodal tumor involvement when multiple intense foci of tracer uptake are identified, FDG-PET is not routinely recommended for axillary staging of patients with newly diagnosed breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
The Sentinel Node in Breast Cancer — A Multicenter Validation Study
Krag, D., Weaver, D., Ashikaga, T., Moffat, F., Klimberg, V. S., Shriver, C., Feldman, S., Kusminsky, R., Gadd, M., Kuhn, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391401 · Cited by 2,018
(2001) · PubMed · Cited by 943
Wahl, R. L., Zasadny, K., Helvie, M., Hutchins, G. D., Weber, B., & Cody, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2101 · Cited by 605
Self-citationAvril, N., Rosé, C. A., Schelling, M., Dose, J., Kuhn, W., Bense, S., Weber, W., Ziegler, S., Graeff, H., & Schwaiger, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3495 · Cited by 557
Wahl, R. L., Cody, R. L., Hutchins, G. D., & Mudgett, E. E. (1991) · Radiology · doi:10.1148/radiology.179.3.2027989 · Cited by 431
Self-citationEvaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler, L. P., Crowe, J. P., al-Kaisi, N. K., & Sunshine, J. L. (1993) · Radiology · doi:10.1148/radiology.187.3.8497624 · Cited by 372
Kwan, W., Jackson, J., Weir, L. M., Dingee, C., McGregor, G., & Olivotto, I. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.018 · Cited by 357
Statistical Comparison of Two ROC-curve Estimates Obtained from Partially-paired Datasets
Metz, C. E., Herman, B. A., & Roe, C. A. (1998) · Medical Decision Making · doi:10.1177/0272989x9801800118 · Cited by 338
Sugawara, Y., Zasadny, K. R., Neuhoff, A. W., & Wahl, R. L. (1999) · Radiology · doi:10.1148/radiology.213.2.r99nv37521 · Cited by 265
Self-citation
Cited by
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“76 (area under the curve) (95) in over 300 patients evaluated independently by each reader.”
BackgroundSelf-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., Dang, C., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0030 · Cited by 951
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Self-citationSchnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8375 · Cited by 649
Veronesi, U., Boyle, P., Goldhirsch, A., Orecchia, R., & Viale, G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66546-4 · Cited by 542
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Breast cancer diagnosis: Imaging techniques and biochemical markers
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26379 · Cited by 410
Blodgett, T. M., Meltzer, C. C., & Townsend, D. W. (2007) · Radiology · doi:10.1148/radiol.2422051113 · Cited by 387
Axillary Nodal Evaluation in Breast Cancer: State of the Art
Chang, J. M., Leung, J. W. T., Moy, L., Ha, S. M., & Moon, W. K. (2020) · Radiology · doi:10.1148/radiol.2020192534 · Cited by 387
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
Ben-Haim, S., & Ell, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054205 · Cited by 351
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0037 · Cited by 304
Performance of FDG PET/CT in the Clinical Management of Breast Cancer
Groheux, D., Espié, M., Giacchetti, S., & Hindié, E. (2013) · Radiology · doi:10.1148/radiol.12110853 · Cited by 271
FDG PET, PET/CT, and Breast Cancer Imaging
Rosen, E. L., Eubank, W. B., & Mankoff, D. A. (2007) · RadioGraphics · doi:10.1148/rg.27si075517 · Cited by 265
Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology
Ziai, P., Hayeri, M. R., Salei, A., Salavati, A., Houshmand, S., Alavi, A., & Teytelboym, O. M. (2016) · RadioGraphics · doi:10.1148/rg.2016150102 · Cited by 106
Fledelius, J., Khalil, A., Hjorthaug, K., & Frøkiær, J. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0223-6 · Cited by 24
Sørensen, J. S., Vilstrup, M. H., Holm, J., Vogsen, M., Bülow, J. L., Ljungstrøm, L., Braad, P.-E., Gerke, O., & Hildebrandt, M. G. (2020) · Diagnostics · doi:10.3390/diagnostics10121001 · Cited by 10
Metadata
- Authors
- Wahl, R. L., Siegel, B. A., Coleman, R. E., & Gatsonis, C. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-01-15
- Volume
- 22
- Issue
- 2
- Pages
- 277-285
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2031950319
- Cited by
- 345
- References
- 30
- FWCI
- 24.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.